


**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Samuel J. DuBoff
Type or print name


Signature

December 3, 2003
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

WANG ET AL.

APPLICATION NO: 10/630,278

FILED: JULY 30, 2003

FOR: COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED
AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 10/038,306 filed January 2, 2002, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(203) 677-7787



Samuel J. DuBoff
Attorney for Applicants
Reg. No. 25,969

Date: 12/3/03

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
GY-85B CIP2
APPLICATION NO.
10/630,278
APPLICANT
Wang et al.
FILING DATE
July 30, 2003

Group --

DEC 05 2003

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,124,327	6/23/92	W. J. Greenlee, et al			
	AB	5,424,329	6/13/95	D. H. Boschelli, et al			
	AC	5,023,265	6/11/91	M. H. Scherlock, et al			
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AI	WO 00/76521A1	12/21/00	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AJ	EP 0530907A1	3/10/93	European Patent Application			<input type="checkbox"/>	<input type="checkbox"/>
	AK	WO 93/01181	1/21/93	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AL	WO 95/04742	2/16/95	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AM	WO 96/11929	4/25/96	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 00/71535	11/30/00	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 01/62255	8/30/01	PCT Application			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>
	AR						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AS	M. Font, et al, "Indoles and Pyridazino[4,5-b]Indoles as Nonnucleoside Analog Inhibitors of HIV-1 Reverse Transcriptase," EUR. J. MED. CHEM., 30 , pp. 963-971, 1995
	AT	D. L. Romero, et al, J. MED. CHEM., 36 , pp. 1505-1508, 1993
	AU	S. D. Young, et al, "2-Heterocyclic Indole-3-Sulfones as Inhibitors of HIV-1 Reverse Transcriptase," BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 5 (5), pp. 491-496, 1995


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.
GY-85B CIP2
APPLICATION NO.
10/630,278
APPLICANT
Wang et al.
FILING DATE
July 30, 2003

Group --

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AV	M. J. Genin, et al, "Synthesis and Bioactivity of Novel Bis(Heteroaryl)Piperazine (BHAP) Reverse Transcriptase Inhibitors: Structure-Activity Relationships and Increased Metabolic Stability of Novel Substituted Pyridine Analogs," J. MED. CHEM., 39 , pp. 5267-5275, 1996
AW	R. Silvestri, et al, ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 9 , pp. 139-148, 1998
AX	A. Fredenhagen, et al, "Semicochlordinol A and B: Inhibitors of HIV-1 Protease and EGF-R Protein Tyrosine Kinase Related to Asterrquinones Produced by the Fungus <i>Chrysosporium Merdarium</i> ," JOURNAL OF ANTIBIOTICS, 50 (5), pp. 395-401, 1997
AY	M. Kato, et al, "New 5-HT ₃ (Serotonin-3) Receptor Antagonists. IV. Synthesis and Structure-Activity Relationships of Azabicycloalkaneacetamide Derivatives," CHEM. PHARM. BULL., 43 (8), pp. 1351-1357, 1995
AZ	V. Levacher, et al, "Broadening in the Scope of NADH Models by Using Chiral and Non-Chiral Pyrrolo [2,3-b]Pyridine Derivatives," TETRAHEDRON, 47 (3), pp. 429-440, 1991
BA	
BB	
BC	
BD	
BE	
BF	
BG	
BH	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.